Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Actavis buys Warner Chilcott for $8.1bn

Executive Summary

Specialty pharmaco Actavis Inc. has acquired publicly traded Warner Chilcott PLC (generics) in a stock swap valued at $8.1bn, including the assumption of $3.4bn of debt. The combined company is expected to adopt the name Actavis PLC and will be led by the current Actavis team. WC shareholders will get 0.160 shares of Actavis (equal to $18.62, a 7% premium) for each share they own; WC investors will hold 23% of the new company, which will be located in Ireland and is expected to trade on the NYSE.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Drug Delivery
      • Topical Delivery
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Stock

Related Companies